Abstract:BackgroundForkhead box protein f1 (Foxf1) is associated with cell differentiation, and may be a key player in bone homoeostasis. However, the effect of Foxf1 on osteogenesis of bone marrow-derived mesenchymal stem cells (BMSCs) and ovariectomy-induced bone loss, as well as its clinical implications, is unknown.MethodsBy quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) and western blotting, we assayed Foxf1 expression in bone tissue, BMSCs, and bone marrow-derived macrophages (BMMs), derived from ovariectomised (OVX) mice, and during osteogenic differentiation and osteoclast differentiation. Using a loss-of-function approach (small interfering RNA [siRNA]-mediated knockdown) in vitro, we examined whether Foxf1 regulates osteoblast differentiation of BMSCs via the Wnt/β-catenin signalling pathway. Furthermore, we assessed the anabolic effect of Foxf1 knockdown (siFoxf1) in OVX mice in vivo. We also assayed the expression of Foxf1 in bone tissue derived from postmenopausal osteoporosis (PMOP) patients and its link with bone mineral density (BMD). Finally, we examined the effect of Foxf1 knockdown on the osteoblastic differentiation of human BMSCs.FindingsFoxf1 expression was significantly increased in bone extract and BMSCs from OVX mice and gradually decreased during osteoblastic differentiation of BMSCs but did not differ significantly in OVX mouse-derived BMMs or during osteoclast differentiation. In vitro, Foxf1 knockdown markedly increased the expression of osteoblast specific genes, alkaline phosphatase (ALP) activity, and mineralisation. Moreover, siFoxf1 activated the Wnt/β-catenin signalling pathway. The siFoxf1-induced increase in osteogenic differentiation was partly rescued by inhibitor of Wnt signalling (DKK1). In OVX mice, Foxf1 siRNA significantly reduced bone loss by enhancing bone formation. Foxf1 expression levels negatively correlated with reduced bone mass and bone formation in bone tissue from PMOP patients. Finally, Foxf1 knockdown significantly promoted osteogenesis by human BMSCs.InterpretationOur findings indicate that Foxf1 knockdown promotes BMSC osteogenesis and prevents OVX-induced bone loss. Therefore, Foxf1 has potential as a biomarker of osteogenesis and may be a therapeutic target for PMOP.

Role of forkhead box O1 in bone remodeling

The Role of Forkhead Box Family in Bone Metabolism and Diseases

Research Progress on Forkhead Box Protein O1 and Bone Metabolism

The Roles of FoxO Transcription Factors in Regulation of Bone Cells Function

The role of FOXO1-mediated autophagy in the regulation of bone formation

FoxO1: a novel insight into its molecular mechanisms in the regulation of skeletal muscle differentiation and fiber type specification

FOXO3 Mediates Tooth Movement by Regulating Force-Induced Osteogenesis

FOXO1 inhibits osteoclastogenesis partially by antagnozing MYC

FOXO1 differentially regulates bone formation in young and aged mice

Foxf1 knockdown promotes BMSC osteogenesis in part by activating the Wnt/β-catenin signalling pathway and prevents ovariectomy-induced bone loss

The Forkhead Box C1, a Novel Negative Regulator of Osteogenesis, Plays a Crucial Role in Odontogenic Differentiation of Dental Pulp Stem Cells

The Roles of FOXO1 in Periodontal Homeostasis and Disease

FOXO1 Mediates RANKL-induced Osteoclast Formation and Activity.

The Forkhead Transcription Factor Foxc2 Stimulates Osteogenesis in MC3T3-E1 Cells

Recent Advances of Osterix Transcription Factor in Osteoblast Differentiation and Bone Formation

Forkhead Box P1 (foxp1) in Osteoblasts Regulates Bone Mass Accrual and Adipose Tissue Energy Metabolism

HIF-1-mediated Expression of Foxo1 Serves an Important Role in the Proliferation and Apoptosis of Osteoblasts Derived from Children's Iliac Cancellous Bone

The Essential Role of FoxO1 in the Regulation of Macrophage Function

FOXO Transcription Factors: Their Clinical Significance and Regulation.

Role and Regulation of Transcription Factors in Osteoclastogenesis

Knockdown of FOXA2 Enhances the Osteogenic Differentiation of Bone Marrow-Derived Mesenchymal Stem Cells Partly Via Activation of the ERK Signalling Pathway